5804-74-0

Upstream product

• 772-33-8 Koshlands reagent I 
• 20277-69-4 sodium methansulfinate 
• 116432-32-7 2-hydroxy-5-nitrobenzyl iodide 

Downstream Products

• 5804-16-0 1-(2-Methylsulfonylmethyl-4-nitro-phenoxy)-heptan 
• 5804-17-1 1-(2-Methylsulfonylmethyl-4-nitro-phenoxy)-nonan 
• 5804-13-7 1-(2-Methylsulfonylmethyl-4-nitro-phenoxy)-propan 
• 5819-62-5 1-Amino-3-methylsulfonylmethyl-4-propoxy-benzol 
• 5819-63-6 1-Amino-3-methylsulfonylmethyl-4-butoxy-benzol 
• 5819-64-7 1-Amino-3-methylsulfonylmethyl-4-pentoxy-benzol 
• 5839-68-9 1-Amino-3-methansulfonylmethyl-4-hexyloxy-benzol 
• 5819-65-8 1-Amino-4-heptyloxy-3-methansulfonylmethyl-benzol 
• 5819-67-0 1-Amino-3-methansulfonylmethyl-4-nonyloxy-benzol 
• 5895-37-4 1.5-Bis-<4-amino-2-methansulfonylmethyl-phenoxy>-pentan 
• 5804-19-3 1-(2-Methylsulfonylmethyl-4-nitro-phenoxy)-5-(2-methylsulfonylmethyl-4-nitro-phenoxy)-pentan 
• 5804-15-9 1-(2-Methylsulfonylmethyl-4-nitro-phenoxy)-hexan 
• 5804-14-8 1-(2-Methylsulfonylmethyl-4-nitro-phenoxy)-pentan 
• 5896-73-1 1-(2-Methylsulfonylmethyl-4-nitro-phenoxy)-butan 

Relevant academic research and scientific papers

CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. For Formula (I) compounds R1, R2, R3, Ar and Z are as defined in the specification. The inventive Formula (I) compounds are inhibitors of CK2 and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer, inflammation and immunological disorders.